Logo


Better science to diagnose and treat cancer

Cancer Targeted Technology is designing and patenting small molecular weight enzyme inhibitors with unique and exceptional imaging and drug delivery properties.


diagnostic

CTT1057
PET Imagine Agent for
Prostate Cancer


therapeutic

CTT1403
Radiotherapeutic for
Prostate Cancer 

Latest News

June 29, 2021

Cancer Targeted Technology Receives Milestone Payment for Development of Diagnostic PET Imaging Agent for Prostate Cancer

August 7, 2020

NIH grants $1.44M to Cancer Targeted Technology to Support the Ongoing Prostate Cancer Clinical Trial of a Promising New Radiotherapeutic, CTT1403

November 6, 2018

Cancer Targeted Technology Files Investigational New Drug Application for CTT1403, a Novel Radiotherapeutic Drug for Prostate Cancer

View All

  • About Us
    • Management
    • Scientific Advisors and Collaborators
  • Technology
    • Relevant Publications
  • Pipeline
    • CTT1057
    • CTT1403
  • Newsroom
    • Press Releases
    • Events and Presentations
  • Careers
  • Contact Us
  • Home
  • About Us
    • Management
    • Scientific Advisors and Collaborators
  • Technology
    • Relevant Publications
  • Pipeline
    • CTT1057
    • CTT1403
  • Newsroom
    • Press Releases
    • Events and Presentations
  • Careers
  • Contact Us
© 2021  Cancer Targeted TechnologyAll rights reservedWebsite Design: Hane Chow, Inc.